Welcome to our dedicated page for Edesa Biotech news (Ticker: EDSA), a resource for investors and traders seeking the latest updates and insights on Edesa Biotech stock.
Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company whose news flow centers on the development of host-directed therapeutics for immuno-inflammatory diseases. Company announcements frequently highlight progress in its two main therapeutic areas, Medical Dermatology and Respiratory, giving investors and observers insight into the status of key clinical programs and funding arrangements.
On this page, readers can follow updates on Edesa’s dermatology pipeline, including news about EB06, an anti-CXCL10 monoclonal antibody candidate being developed as a therapy for vitiligo, and EB01 (1.0% daniluromer cream), a Phase 3-ready asset for moderate-to-severe chronic Allergic Contact Dermatitis. Disclosures often cover manufacturing milestones, regulatory interactions and plans for Phase 2 and Phase 3 clinical studies in these indications.
The news feed also captures developments in Edesa’s respiratory portfolio. This includes clinical data and regulatory context for paridiprubart (EB05), a monoclonal antibody being developed for Acute Respiratory Distress Syndrome (ARDS), as well as information on the U.S. government-funded “Just Breathe” platform study and Canadian government funding from the Strategic Innovation Fund. Announcements may detail Phase 3 study outcomes, safety findings, and the company’s exploration of additional uses for paridiprubart in chronic respiratory diseases and pulmonary fibrosis via EB07.
In addition to clinical and scientific news, Edesa’s releases include financial results, equity financings, at-the-market offering updates, and executive or board changes. Visitors can use this page to monitor how Edesa reports on its operating expenses, government contribution agreements, capital raises and conference participation. For those tracking EDSA, the news section provides a centralized view of the company’s disclosed milestones, strategic priorities and regulatory progress over time.
Edesa Biotech, Inc. (NASDAQ:EDSA) will host a KOL webinar on its lead asset, EB05, for treating Acute Respiratory Distress Syndrome (ARDS) on April 29, 2021 at 1:00 pm ET. KOL Dr. Ted Steiner from the University of British Columbia will discuss the treatment landscape for COVID-19 induced ARDS and answer questions after his presentation. Edesa's Phase 2/3 study aims to evaluate the safety and efficacy of EB05, with enrollment of up to 316 adult COVID-19 patients. An update on patient enrollment will be provided during the event.
Edesa Biotech (NASDAQ:EDSA) announced a definitive license agreement to acquire global rights to a non-steroidal anti-inflammatory technology related to its EB01 and EB02 drug candidates. This agreement enhances Edesa's intellectual property portfolio and allows for broader development and commercialization across various fields, following an earlier licensing from Hebrew University. CEO Par Nijhawan emphasized the importance of this agreement in strengthening Edesa's strategic position. The company has also completed patient enrollment for a Phase 2b trial of EB01 aimed at treating chronic Allergic Contact Dermatitis.
Edesa Biotech (NASDAQ:EDSA) announced the completion of over 50% patient enrollment for the Phase 2 portion of its Phase 2/Phase 3 clinical study of EB05, aimed at treating hospitalized COVID-19 patients at risk of developing Acute Respiratory Distress Syndrome (ARDS). Over 160 out of 316 planned subjects have been randomized. The company is accelerating the process by activating approximately 20 more hospital sites. Dr. Par Nijhawan highlighted the unmet medical need for ARDS treatment, emphasizing the importance of this milestone in their efforts to address severe cases of COVID-19.
Edesa Biotech (NASDAQ:EDSA) recently announced the completion of enrollment for the first cohort in its Phase 2b clinical study of EB01, targeting chronic Allergic Contact Dermatitis (ACD). A total of 46 subjects were randomized and treated with either EB01 or a placebo. EB01, an sPLA2 inhibitor, aims to reduce inflammation without steroid-related safety concerns. The company will conduct a blinded interim analysis post a 28-day treatment period. Edesa is optimistic about the drug's potential, and if the interim results are favorable, the final study phase will proceed.
Edesa Biotech, Inc. (NASDAQ:EDSA) has successfully closed an underwritten public offering, selling 1,562,500 common shares at $6.40 each, totaling $10 million in gross proceeds. The offering allows for an additional 234,375 shares to be purchased by the underwriter within 30 days. Proceeds will be directed toward general corporate expenses, including capital expenditures and R&D. The company is developing treatments for inflammatory diseases, notably EB05 for ARDS and EB01 for allergic dermatitis. The registration statement for this offering has been effective since September 12, 2019.
Edesa Biotech, Inc. (Nasdaq:EDSA) announced an increased public offering of 1,562,500 common shares at $6.40 each, expected to close around March 2, 2021. The offering aims to raise approximately $10 million for general corporate purposes, including working capital and R&D expenses. H.C. Wainwright & Co. is the book-running manager, with an option for the underwriter to purchase an additional 234,375 shares. This follows a previously declared effective registration statement with the SEC.
Edesa Biotech, Inc. (Nasdaq:EDSA) has entered an underwriting agreement with H.C. Wainwright & Co. for the purchase of 546,875 common shares at $6.40 each. The offering, expected to close by March 2, 2021, aims to raise approximately $3.5 million. Edesa intends to utilize the net proceeds for general corporate purposes, which may include working capital and R&D expenses. Additionally, the underwriter holds a 30-day option for an extra 82,031 shares. The offering is made via a prospectus supplement filed with the SEC.
Edesa Biotech, Inc. (NASDAQ:EDSA) reported financial results for Q1 2021, ending December 31, 2020. The company announced a C$14 million grant from the Canadian government to support its Phase 2 clinical study of EB05 for Acute Respiratory Distress Syndrome (ARDS), associated with COVID-19. Edesa has no revenues for the quarter, with a net loss of $2.64 million or $0.26 per share. Operating expenses rose to $2.61 million, reflecting ongoing R&D efforts. Edesa aims for an interim analysis of the ARDS study soon, while also progressing in a Phase 2b study for chronic allergic contact dermatitis.
Edesa Biotech (NASDAQ:EDSA) has received FDA and Health Canada approval for a sub-study in its Phase 2/3 clinical trial of EB05, aimed at treating Acute Respiratory Distress Syndrome (ARDS) in critically ill COVID-19 patients. This sub-study will include up to 100 ICU patients whose conditions disqualify them from the main study. EB05 works by inhibiting TLR4 signaling, potentially reducing lung inflammation and injury. The ongoing study plans to enroll up to 316 patients, with promising results possibly leading to a pivotal Phase 3 trial.
Edesa Biotech, Inc. (NASDAQ:EDSA) announced that CEO Dr. Par Nijhawan will join a virtual panel discussion titled Canadian Innovative COVID Solutions on January 26, 2021, at 2:20 PM ET. The event, organized by Clinical Trials Ontario, will focus on developing multiple countermeasures to the COVID-19 pandemic, including Edesa's EB05 drug candidate designed to treat Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients. Edesa is advancing innovative treatments for inflammatory and immune-related diseases, with EB05 currently in late-stage clinical studies.